Blood Cancer United Acquires Luvelta for Pediatric Compassionate-Use Program

Blood Cancer United acquired the remaining supplies and the investigational new drug designation of Luvelta, a discontinued cancer medication, on June 11, 2026. The nonprofit will provide the drug at no cost to children with a rare form of blood cancer through a compassionate-use program, according to STAT.

The organization, formerly known as the Leukemia & Lymphoma Society, announced the move Thursday to ensure patients don’t lose access to the medication after its discontinuation. As part of the transaction, Blood Cancer United takes over the management of the compassionate-use program, STAT reports.

The nonprofit will distribute the available Luvelta supplies to eligible pediatric patients until the stock is exhausted.

How will patients access Luvelta?

Patients will receive the medication through a compassionate-use framework managed by Blood Cancer United. This system allows the use of an unapproved drug outside of a clinical trial for patients with serious or life-threatening conditions who have no comparable alternative therapy, according to STAT.

Blood Cancer United is providing the drug at no cost to the children receiving it. The nonprofit’s role is to manage the logistics of distribution and the regulatory requirements associated with the drug’s use.

What is the role of the IND designation in this deal?

Blood Cancer United acquired the investigational new drug (IND) designation along with the physical supplies. An IND is a request for authorization from the FDA to administer an unapproved drug or biological product to humans, according to FDA regulatory standards.

Without the IND designation, a nonprofit or physician cannot legally ship or administer an experimental drug across state lines for clinical purposes. By securing this designation, Blood Cancer United maintains the legal authority to oversee the medication’s distribution to patients who depend on it.

Why did Blood Cancer United intervene?

The intervention follows the discontinuation of Luvelta. When pharmaceutical companies halt the development of an investigational drug, the supply typically vanishes, leaving patients who responded well to the treatment without options. STAT describes the nonprofit’s purchase of the remaining supplies as a rare move.

This action contrasts with standard industry practice, where discontinued assets are often written off or destroyed. By stepping in, Blood Cancer United prevents an immediate cessation of treatment for children with this specific rare blood cancer.

What happens when the supplies run out?

The current arrangement only lasts while supplies last. Blood Cancer United is distributing the remaining inventory of the discontinued drug, but the report does not indicate plans for new manufacturing of Luvelta.

Once the remaining stock is depleted, patients will likely need to transition to other available therapies or enroll in different clinical trials, depending on their medical status and the availability of alternative treatments for their specific form of cancer.